These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effects of glutamate-related drugs on anxiety and compulsive behavior in rats with obsessive-compulsive disorder. Zhan Y; Xia J; Wang X Int J Neurosci; 2020 Jun; 130(6):551-560. PubMed ID: 31680595 [No Abstract] [Full Text] [Related]
25. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. Goodman WK; Storch EA; Sheth SA Am J Psychiatry; 2021 Jan; 178(1):17-29. PubMed ID: 33384007 [TBL] [Abstract][Full Text] [Related]
26. Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Kvale G; Hansen B; Hagen K; Abramowitz JS; Børtveit T; Craske MG; Franklin ME; Haseth S; Himle JA; Hystad S; Kristensen UB; Launes G; Lund A; Solem S; Öst LG JAMA Netw Open; 2020 Aug; 3(8):e2013249. PubMed ID: 32789516 [TBL] [Abstract][Full Text] [Related]
27. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Keuneman RJ; Pokos V; Weerasundera R; Castle DJ Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020 [TBL] [Abstract][Full Text] [Related]
28. Suicidality in a 27-year-old Male with Obsessive Compulsive Disorder. Ross BM; Lee JD; Espiridion ED Cureus; 2018 Dec; 10(12):e3804. PubMed ID: 30868018 [TBL] [Abstract][Full Text] [Related]
29. Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice. Davis GL; Minerva AR; Lario A; Simmler LD; Rodriguez CI; Gunaydin LA Nat Commun; 2021 Oct; 12(1):6040. PubMed ID: 34654803 [TBL] [Abstract][Full Text] [Related]
30. How willing are you? Willingness as a predictor of change during treatment of adults with obsessive-compulsive disorder. Reid AM; Garner LE; Van Kirk N; Gironda C; Krompinger JW; Brennan BP; Mathes BM; Monaghan SC; Tifft ED; André MC; Cattie J; Crosby JM; Elias JA Depress Anxiety; 2017 Nov; 34(11):1057-1064. PubMed ID: 28715850 [TBL] [Abstract][Full Text] [Related]
31. Clinician-reported barriers to using exposure with response prevention in the treatment of paediatric obsessive-compulsive disorder. Keleher J; Jassi A; Krebs G J Obsessive Compuls Relat Disord; 2020 Jan; 24():100498. PubMed ID: 32140386 [TBL] [Abstract][Full Text] [Related]
32. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Zohar J; Zohar-Kadouch RC; Kindler S Drugs; 1992 Feb; 43(2):210-8. PubMed ID: 1372219 [TBL] [Abstract][Full Text] [Related]
36. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. Niciu MJ; Grunschel BD; Corlett PR; Pittenger C; Bloch MH J Psychopharmacol; 2013 Jul; 27(7):651-4. PubMed ID: 23676198 [TBL] [Abstract][Full Text] [Related]
37. Orgasm, Serotonin Reuptake Inhibition, and Plasma Oxytocin in Obsessive-Compulsive Disorder. Gleaning From a Distant Randomized Clinical Trial. Humble MB; Bejerot S Sex Med; 2016 Sep; 4(3):e145-55. PubMed ID: 27320409 [TBL] [Abstract][Full Text] [Related]
38. Ziprasidone Augmentation in an Adolescent with Obsessive Compulsive Disorder: A Case Report. Demirkaya SK; Alyanak B Psychopharmacol Bull; 2016 Mar; 46(1):73-76. PubMed ID: 27738375 [TBL] [Abstract][Full Text] [Related]
39. An Avoidance-Based Rodent Model of Exposure With Response Prevention Therapy for Obsessive-Compulsive Disorder. Rodriguez-Romaguera J; Greenberg BD; Rasmussen SA; Quirk GJ Biol Psychiatry; 2016 Oct; 80(7):534-40. PubMed ID: 27086546 [TBL] [Abstract][Full Text] [Related]
40. A review of the role of serotonin system genes in obsessive-compulsive disorder. Sinopoli VM; Burton CL; Kronenberg S; Arnold PD Neurosci Biobehav Rev; 2017 Sep; 80():372-381. PubMed ID: 28576508 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]